生三七对肝纤维化小鼠血液流变学的影响

目的:观察生三七对肝纤维化小鼠血液流变学的影响。方法:复制小鼠中毒性肝纤维化模型,生三七粉灌胃6周,检测全血粘度、血浆粘度、红细胞压积等血液流变学参数,并行肝脏病理组织切片检测。结果:与空白对照组比较,肝纤维化模型组小鼠全血粘度、血浆粘度、红细胞压积明显增高(P<0.05,P<0.01),生三七治疗后小鼠全血粘度、血浆粘度、红细胞压积明显降低(P<0.05,P<0.01);肝脏病理组织切片显示使用生三七后,肝纤维化程度有明显改善。结论:生三七可降低血液粘度,延缓肝纤维化的发展。     

重组2型腺相关病毒-转化生长因子β3对实验性肝纤维化大鼠肝脏组织病理学和Ⅰ型胶原表达的影响

Objective To investgate the effects of TGF β 3 on rat hepatic fibrosis. Methods The TGF β 3 cDNA was cloned into rAAV2 vector. Rats were randomly divided into four groups: normal control group, model group, negative control group and TGF β 3 group. Hepatic fibrosis was induced by hypodermic injection of 40% CCI4. Recombinant AAV2-TGF β 3 viral particles were injected via the vena caudalis one week before CCh treatment. Rats were executed 8 weeks after CCI4 treatment, global histological change was observed after HE staining, the distribution of the collagen fibers was observed after masson staining, his-tochemistry was done to observe the expression of collagen Ⅰ; The positive area rate of the collagen fibers and the average optical rate of collagen Ⅰ were quantified. Results HE staining indicated that collagen fibers were reduced in the TGF β 3 group. Masson staining shown that the collagen fibers were distributed around the blood vessel, in the portal area and disse space. Compared to the model group (13.2%±2.2%) and negative control group (12.3%±1.5%), the collagen fibers in liver tissues of TGF β3 group (7.7% ± 1.5%) were significantly decreased (q = 9.456, P < 0.01; q = 8.217, P < 0.01). Histochemistry indicated that the collagen fibers of liver tissues of TGF 15 3 group (0.185±0.033) were significantly higher than those in the model group (0.252±0.042) and the negative control group (0.230±0.029), (q = 6.228, P < 0.01; q = 4.346, P < 0.01). Conclusion TGF β 3 alleviates the damage to hepatic cell and the level offibrosis in CCI4 treated rats and inhibits the expression of collagen Ⅰ.     

结缔组织生长因子在慢性乙型肝炎和肝硬化中的表达

肝纤维化是肝组织在各种炎性因子的刺激下产生的一种病理反应，与肝细胞外基质大量沉积有关，其分子机制尚不完全清楚，新近研究表明．结缔组织生长因子（CTGF）是转化生长因子（TGF）的下游效应介质．在活体中可以诱导纤维母细胞细胞外基质成分基因的表达。我们对慢性乙型肝炎和肝炎肝硬化患者的肝活检标本进行CTGF的免疫组化染色研究．以期探讨CTGF的肝内表达及其与肝纤维化和肝硬化的关系。     

首部《慢性乙型肝炎防治指南》（三）

9治疗的总体目标 慢性乙型肝炎治疗的总体目标是：最大限度地长期抑制或消除HBV，减轻肝细胞炎症坏死及肝纤维化，延缓和阻止疾病进展，减少和防止肝脏失代偿、肝硬化、HCC及其并发症的发生，从而改善生活质量和延长存活时间。     

益气化瘀方治疗慢性乙型肝炎肝纤维化50例临床观察

目的观察益气化瘀方对慢性乙型肝炎肝纤维化的临床疗效。方法选符合标准的慢性乙型肝炎肝纤维化患者100例,随机分为2组。治疗组50例予益气化瘀方,对照组50例口服大黄虫丸,治疗3个月。结果治疗组显效20例,有效21例,无效9例,总有效率为82.0%(95%CI=73.4%~92.7%);对照组显效11例,有效13例,无效26例,总有效率为48.0%(95%CI=34.2%~61.8%);两组综合疗效比较,有显著性差异(u=3.0449,P=0.0041);且两组总有效率的95%CI不重叠;并可改善B超及肝纤维化相关参数(P<0.05)。结论益气化瘀方治疗慢性乙型肝炎肝纤维化疗效优于大黄虫丸,其收益为OR=0.2(95%CI=0.08~0.50),NNT=3(95%CI=1.9~6.5)。     

曲尼司特对慢性阻塞性肺疾病大鼠细胞外基质重塑的干预

以胶原为主的细胞外基质（ECM）在气道壁的过度沉积是引起慢性阻塞性肺疾病（COPD）气流阻塞的重要原因。研究结果显示结缔组织生长因子（CTGF）可促进ECM合成，近年来发现曲尼司特可以治疗纤维化疾病，但其对于COPD的作用报道不多。本研究的目的是观察并探讨曲尼司特对COPD大鼠ECM重塑过程的影响及其可能的作用机制。     

腹膜后纤维化3例

腹膜后纤维化临床上比较少见，本院自2002年以来收治3例，行腹腔镜及开放手术各1例，单纯输尿管置双J管1例，报告如下。